European Market Access
Inter-Pharma supports manufacturers entering Central European markets, from market analysis and listings to launch and operational distribution.
Discuss your project →Inter-Pharma expertise
The starting brief records product status, target population, pack and language variants, data needs, distribution channel and country sequence. Reimbursement, marketing authorisation and operational distribution remain distinct but coordinated workstreams.
Depending on the product, the plan considers AMNOG and G-BA processes in Germany, SÚKL pricing and reimbursement routes in Czechia and applicable EU HTA steps. Inter-Pharma does not replace legal, reimbursement or authority advice; it connects confirmed requirements with operational launch planning.
Article and pack data, identifiers, price and distribution status, listing partners, inventory model and delivery milestones are combined in a controlled readiness plan. Launch begins only after data, ownership and interfaces are confirmed.
GDP requirements, storage and temperature profile, traceability, complaints, recalls, transport and quality agreements are clarified before the first order. Inter-Pharma's own warehousing and picking in Cheb are used only when product, authorisations and project scope fit.
A shared action plan links approvals, initial stock, order readiness, supply performance, escalation and review dates. Early market and delivery data are assessed against agreed objectives without promising availability or market success.
Inter-Pharma turns a planned market entry into an auditable operational launch plan. The focus is on product and status data, listings, launch stock, GDP-compliant warehousing and distribution, and post-launch supply performance—clearly separated from marketing-authorisation, HTA, pricing and reimbursement decisions.
Updated: 19 September 2026 · Professionally reviewed by Martin Didunyk
It connects confirmed regulatory and commercial requirements with product data, listings, launch stock, GDP warehousing, order readiness and distribution. It does not replace marketing authorisation, HTA, pricing or reimbursement advice.
A launch is supply-ready only when product status, temperature, batch, expiry, safety stock, recipients, interfaces and escalation are controlled in the warehouse process. Warehouse planning therefore starts before the first inbound delivery.
Once requirements, documentation, roles and interfaces are fully agreed, larger projects can typically be onboarded within two to three weeks. Product qualification, data migration and testing may alter the timeline.
The site has 20,000 pallet positions in total. Available capacity, the appropriate storage zone and product acceptance are confirmed for each product and volume profile.
Requirements depend on product, activity, role, origin, target market and recipient. The MAH, wholesalers and other parties must evidence their specific scope; no blanket clearance is assumed.
Stock status, batches and recipients remain traceable. Blocking, retrieval, quarantine, assessment, reporting and final disposition follow the agreed quality and escalation process.
No. Inter-Pharma maps these dependencies into the country and launch plan but does not replace formal benefit assessment, legal advice, pricing or reimbursement negotiation.
Provide the product and marketing status, MAH and roles, target countries, pack variants, temperature, SKUs and volumes, launch date, channels and recipients, data and interface requirements, and the status of pricing, reimbursement and listings.
The applicable route depends on product status, indication and target market. Current decisions and procedures of the competent authorities remain decisive.
Central European location
Cheb lies in western Czechia, directly at the German border. The location connects Bavaria, Saxony, Austria and Poland with short access routes to Central and Eastern Europe.
Approximate straight-line distances, rounded to 10 km. Actual road distances vary by route.
This page directly addresses the following professional and commercial searches:
pharma market access Germany is relevant when product, regulatory status, temperature, volume, recipients, target markets and required process steps need to be assessed together. Inter-Pharma confirms the exact scope only after this project review.
At minimum, provide product type and status, temperature range, average and maximum stock, SKU and movements, recipients and destination countries, requested start, interfaces and additional services.
We structure your needs and connect the right partners and processes.